![]() ![]() ![]() Panel 2 had 58 HIV-1-positive serum samples, including 38 HIV-1 subtype B serum samples and 20 HIV-1 non-subtype B serum samples. Panel 1 had 57 HIV-1/HIV-2-negative serum samples obtained from individuals with no documented HIV infection all were negative using a screening immunoassay. Screening immunoassays were performed according to the manufacturer’s instructions. All samples were repeatedly reactive using a screening immunoassay, such as Architect from Abbott Laboratories or GS HIV-1/HIV-2 Plus O EIA from Bio-Rad Laboratories (HIV-1/HIV-2 Plus O EIA). All specimens used in this study are residual samples collected for routine diagnostic purposes. The LSPQ is the Public Health Laboratory of the Province of Quebec, where confirmation of HIV infection is performed. The performance of this new confirmatory assay to detect early infections, to reduce the rate of indeterminate status, and to confirm HIV-1 infection in cadaveric blood samples makes Geenius a potent reliable alternative to the WB.Ī total of 370 retrospective diagnostic samples collected from 356 patients were obtained from the Laboratoire de Santé Publique du Québec (LSPQ) serobank collection. ![]() Our results indicate that the Bio-Rad Geenius HIV 1/2 rapid test exhibits better sensitivity to detect HIV-1 infections and better performance than WB to confirm and differentiate between HIV-1 and HIV-2 infections. Ninety cadaveric samples (54 negative, 23 HIV-1 positive, and 3 HIV-1 indeterminate) were tested with Geenius, leading to a sensitivity of 100%, a specificity of 96%, and an indeterminate rate of 4%. However, 7% and 10% of them were indeterminate with Geenius and WB, respectively, leading to a specificity rate of 93% for Geenius and 90% for WB. None of the HIV-negative samples were positive using Geenius or WB. Three of 10 patients presenting with an early HIV infection (1 to 2 weeks before seroconversion by WB) were positive using Geenius. Geenius reduced the number of indeterminate results by 85% and exhibited a differentiation capacity for HIV-1 and HIV-2 of 100% and 89%, respectively. Sensitivity of the Geenius assay to detect HIV-1 and HIV-2 infections was 100% and 97%, respectively, and that of the WB assay was 86% and 39%, respectively. A total of 370 retrospective samples collected from 356 patients were tested. The rapid confirmatory Bio-Rad Geenius HIV 1/2 assay was evaluated as an alternative to the HIV-1 Western blot (WB) confirmatory assay. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |